Tirzepatide Shows Superior Glaucoma Protection Compared to GLP-1 Receptor Agonists in Type 2 Diabetes Patients

A large retrospective cohort study has revealed that tirzepatide查看药品详情, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), significantly reduces the risk of glaucoma-related complications compared to selective GLP-1 receptor (搜索)搜索该靶点 agonists in patients with type 2 diabetes mellitus (搜索)搜索该疾病. The analysis of 83,698 patients found tirzepatide initiation was associated with a 50% lower risk of primary open-angle glaucoma (搜索)搜索该疾病 development.

Study Design and Patient Population

The retrospective clinical cohort study utilized data from the U.S. Collaborative Network within the TriNetX platform, encompassing 71 healthcare organizations across the United States from June 2022 to May 2025. Researchers identified 41,850 individuals who initiated tirzepatide查看药品详情 and 147,828 patients who began selective GLP-1 receptor (搜索)搜索该靶点 agonist therapy.

Following one-to-one propensity score matching to balance demographics, comorbidities, medication use, and ophthalmic encounters between groups, 41,849 patients remained in each cohort. The study excluded patients with prior exposure to either drug class, recent addition of second-line antihyperglycemic therapy, existing glaucoma diagnosis, prior glaucoma surgery, or ocular trauma.

Baseline Characteristics and Treatment Distribution

Before matching, the tirzepatide查看药品详情 group was younger (mean age 55.1 years versus 56.6 years) and had a higher proportion of white patients (70.5% versus 63.8%). The tirzepatide cohort also demonstrated lower rates of chronic kidney disease (搜索)搜索该疾病 (10.3% versus 13.5%), decreased insulin查看药品详情 use (29.9% versus 35.4%), higher body mass index (38.1 kg/m² versus 36.8 kg/m²), and lower hemoglobin A1c levels (7.3 versus 7.6).

In the GLP-1 receptor (搜索)搜索该靶点 agonist cohort, semaglutide查看药品详情 comprised 76.4% of treatments, followed by dulaglutide查看药品详情 at 18.1%, liraglutide查看药品详情 at 5.1%, lixisenatide at 0.3%, and exenatide at 0.1%.

Significant Risk Reductions Across Glaucoma Outcomes

The study demonstrated substantial protective effects of tirzepatide查看药品详情 across multiple glaucoma-related endpoints. Compared to selective GLP-1 receptor (搜索)搜索该靶点 agonists, tirzepatide initiation was associated with a risk ratio of 0.50 (95% CI: 0.34-0.74) for primary open-angle glaucoma (搜索)搜索该疾病 development, representing a 50% risk reduction.

For ocular hypertension (搜索)搜索该疾病, tirzepatide查看药品详情 showed a risk ratio of 0.59 (95% CI: 0.40-0.88), indicating a 41% lower risk. The need for first-line glaucoma treatment, including medication or surgery, was reduced with a risk ratio of 0.54 (95% CI: 0.45-0.64), demonstrating a 46% risk reduction.

Consistent Benefits Across Patient Subgroups

Risk reductions remained consistent among patients using concomitant metformin查看药品详情 or insulin查看药品详情 therapy. Sensitivity analyses restricted to patients aged 60 years or older yielded comparable findings, supporting the robustness of the association across different age groups.

Additional comparisons with individual selective GLP-1 receptor (搜索)搜索该靶点 agonists, including semaglutide查看药品详情 and dulaglutide查看药品详情, showed consistent trends favoring tirzepatide查看药品详情, further validating the study's primary findings.

Potential Mechanisms and Clinical Implications

The study authors noted that while GLP-1 receptor (搜索)搜索该靶点 agonists have been proposed to offer neuroprotective effects, the data suggest that dual incretin therapy may confer additional ocular benefits. "Our findings suggest that tirzepatide查看药品详情, through its dual GIP/GLP-1 action, may be superior as a non-IOP-lowering adjunct or even as a primary preventive agent in glaucoma management among patients with diabetes," the researchers explained.

The consistent trends in lowered risk of glaucoma and glaucoma treatment suggested a broader therapeutic role for incretin-based therapies in ocular health management, with tirzepatide查看药品详情 potentially amplifying this benefit beyond glucose control mechanisms.

Study Limitations and Future Research Directions

The investigators acknowledged key limitations, including the observational study design that prevents causality inference from the analysis. Additionally, the short follow-up period may insufficiently capture the chronic trajectory of glaucoma development, particularly considering tirzepatide查看药品详情's recent FDA approval.

The findings highlight the need for further research to clarify underlying mechanisms and explore the potential role of tirzepatide查看药品详情 in glaucoma prevention and management among patients with type 2 diabetes mellitus (搜索)搜索该疾病. Future studies should investigate the physiological mechanisms underlying these protective effects beyond glucose control.